This site is intended for health professionals only
Following the completion of the European Mutual Recognition Procedure, Rapydan (70 mg lidocaine/70 mg tetracaine medicated plaster) has gained marketing authorisation in various European countries.
The treatment, for pain relief associated with needle puncture and cannulation, is approved in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal.
Rapydan obtained regulatory marketing authorisation in Sweden in January 2007. EUSA Pharma, the manufacturers of the medication, began launching Rapydan in other European Union countries starting early in 2008.
â€œSince the launch of Rapydan in Sweden in 2007, the plaster has been broadly received among the healthcare community,â€ said Stefan Lundeberg, MD, Pain Treatment Service, Department of Paediatric Anaesthesia and Intensive Care at Astrid Lindgren Children’s Hospital, Karolinska University Hospital.
â€œThe use of Rapydan has already widely impacted the relief of pain associated with needle punctures and cannulations, especially among children, throughout Sweden, and is a long-awaited addition to our pain relief armoury in the field of topical anaesthesia.â€
Venepuncture and IV insertions are the two most common sources of pain in hospitalised children. In fact, IV insertions and blood draws were the most frequently reported painful events.
Rapydan is indicated for surface anaesthesia of normal intact skin in connection with needle puncture in adults and children from 3 years of age. It is also indicated for cases of superficial surgical procedures on normal intact skin in adults.